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share the work provObjective: Use of zidovudine (ZDV) in antiretroviral therapy is limited by toxicity and
twice daily (b.i.d.) dosing. Fozivudine (FZD) is a ZDV prodrug, which is activated
intracellularly to ZDV-monophosphate especially in mononuclear cells but not in bone
marrow cells. FZD promises improved myelotoxicity and once daily (o.d.) dosing.
Design: Randomized clinical trial.
Methods: We conducted an open-label, phase II, proof-of-concept trial investigating
three different FZD doses (800 mg o.d., 600 mg b.i.d., 1200 mg o.d.) versus ZDV
(300 mg b.i.d.) in combination with lamivudine and efavirenz in HIV-infected, ART-
naive patients from Tanzania and Côte d’Ivoire. The primary objective was to demon-
strate virological efficacy after 24 weeks in intent-to treat and per-protocol analysis.
Secondary endpoints included safety and pharmacokinetic outcomes.
Results: Of 119 participants included in the intent-to treat analysis, HIV RNA less than
50 copies/ml at 24 weeks was observed in 64 of 88 (73%) patients in the combined FZD
arms versus 24 of 31 (77%) in the ZDV arm (RR 0.94, 95% confidence interval 0.75–
1.18). In the per-protocol analysis, responses were 64 of 77 (87%) versus 23 of 29 (79%),
respectively (RR 1.09, 95% confidence interval 0.89–1.34). Outcomes were similar
between FZD arms. Overall, treatments were well tolerated. Severe or worse anaemia
occurred in two cases (one related to FZD, one to ZDV), grade III/IV neutropenia was
less frequent in FZD compared with ZDV arms (22 versus 42%, P¼0.035). Pharma-
cokinetic analysis supported o.d. administration of FZD.
Conclusion: Virological 24-week efficacy was demonstrated in b.i.d. and o.d. admi-
nistered FZD-based regimens. Reduced myelotoxicity of FZD needs to be confirmed in
a larger trial. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2017, 31:501–509Keywords: Africa, antiretroviral therapy, fozivudine, HIV, zidovudine Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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502 AIDS 2017, Vol 31 No 4IntroductionIncreased effectiveness of HIV-1 treatment through
optimizing antiretroviral regimens for simplification
and reduced toxicity is a priority in HIV treatment
recommendations [1].
Zidovudine (ZDV) has been widely used as part of
antiretroviral regimens, but is no longer recommend as
first choice because its use is limited by twice daily (b.i.d.)
dosing and haematologic toxicity [1–3]. However, ZDV
exhibits important characteristics, notably related to drug
resistance pattern relevant for antiretroviral treatment
strategies in nonsubtype B HIV-1 strains from Africa
when compared with other nucleoside/nucleotide
reverse transcriptase inhibitors (NRTI) [4,5]. To over-
come the above limitations of ZDV, the availability of an
improved thymidine-analogue NRTI would be of great
value, especially in African countries where anaemia and
neutropenia are frequent, and monitoring for toxicity and
adherence is often limited [6,7].
Fozivudine tidoxil is a thioether lipid–ZDV conjugate.
After intake it is split intracellularly into the lipid moiety
and ZDV-monophosphate, which is subsequently phos-
phorylated to the active metabolite ZDV-triphosphate.
The rationale behind the development of fozivudine
(FZD) was to take advantage of the high cleavage activity
in mononuclear cells and other organs resulting in
increased amounts of intracellular ZDV available for
phosphorylation to the active metabolite, and a very low
activity in red blood and stem cells, which should result in
reduced haematologic toxicity [unpublished data on file
at Boehringer Mannheim].
FZD was studied in four phase I/II clinical trials in HIV-
infected, treatment-naive patients in Europe and the
United States. FZD o.d. and b.i.d. daily administered
single oral doses were evaluated up to 1800 mg/day over 1
week, showing a dose linear increase of pharmacokinetic
parameters and good tolerability [8,9]. A bioavailability
study of FZD under fed and fasting conditions revealed no
clinically relevant pharmacokinetic differences, indicating
that the drug can be given without regard to timing of
meals [unpublished data on file at Boehringer Man-
nheim]. In a single FZD, multiple dose-finding, phase II
study, the largest viral load reduction after 4 weeks was
seen with 600 mg b.i.d. (0.67 log) with a similar
reduction observed in the 800 mg o.d. group [10].
The further development of FZD was halted during the
early millennium mainly because of marketing consider-
ations at this time. Based on an expected greatest benefit
of the drug in African HIV-infected populations, we
designed a study with the objective to demonstrate
treatment efficacy, tolerability, and pharmacokinetics of
o.d. and b.i.d. administered FZD-based antiretroviral
regimens in African treatment-naive patients. Copyright © 2017 Wolters Kluwer HMethods
Study design and population
The Fozivudine in Africa Trial Initiative (FATI-1) was an
open-label, multicentre, prospective, randomized, phase
IIa, proof-of-concept study, aiming to demonstrate 24-
week treatment efficacy comparing three different doses
of FZD (600 mg b.i.d., 800 mg o.d., 1200 mg o.d.) and
standard ZDV (300 mg b.i.d.) in combination with
lamivudine (3TC either 150 mg b.i.d. or 300 mg o.d.) and
efavirenz (EFV 600 mg o.d.) in HIV-infected, ART-naive
patients. The study was conducted at two African centres:
the National Institute for Medical Research (NIMR)-
Mbeya Medical Research Center in collaboration with
the Mbeya Referral Hospital in Mbeya, Tanzania, and the
Service de Maladies Infectieuses et Tropicales (SMIT) at
the CHU Treichville Hospital in collaboration with the
PACCI Program in Abidjan, Côte d’Ivoire.
The study protocol aimed to include 120 patients aged 18
years or above, with an indication to start ARTaccording to
WHO and/or country guidelines. Laboratory inclusion
criteria were: CD4þ cell count at least 100 cells/ml,
haemoglobin (Hb) at least 9.5 g/dl, platelets at least 50 000
cells/ml, neutrophils at least 500 cells/ml, bilirubin and
alanine aminotransferase (ALT) less than 2.5-fold upper
limit of normality, no severe hepatic insufficiency
(prothrombin time< 50%), creatinine clearance calculated
by Cockroft’s formula at least 50 ml/min, and only trace or
below protein and blood in the urine dipstick test. Women
were excluded if pregnant or breastfeeding. Furthermore,
we excluded patients with evidence of an HIV-2 infection
(Abidjan only), hepatitis B coinfection, and presence of a
severe uncontrolled, ongoing disease.
The investigational FZD was provided as 200 mg film-
coated tablets. ZDV, 3TC, andEFV were distributedbyeach
country’s National AIDS Control Programme. A master
randomization list containing 60 sequential randomization
slots was provided to each study centre and block
randomization was performed containing four assignments
per block for each of the study arms. The sequence of each
arm per block was randomly distributed using the certified
web-based custom software system ALEA (FormsVision
BV, 1391 GTAbcoude, The Netherlands). Randomization
was stratified by centre and sex with 30 patients per arm (15
patients per arm and site). A minimum of 30%
representation for each sex was requested per arm and site.
This study was registered with ClinicalTrials.gov
(NCT01714414) and the WHO International Clinical
Trials Registry Platform (PACTR201205000384379).
Ethical and regulatory approval was obtained from the
institutional review board of the Mbeya Medical
Research Ethics Committee, NIMR Ethics Committee
and the Tanzania Food and Drugs Authority (TFDA) in
Tanzania, the Comité National d’Ethique et de la
Recherche (CNER) and the Direction de la Pharmacieealth, Inc. All rights reserved.
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and the Ethics Committee of Munich University
(Ludwig-Maximilians-Universität) in Germany. All
patients received detailed oral and written study
information and provided written informed consent.
Procedures
All patients were requested to take their drugs with or
without food at about the same times each day. Study drugs
were dispensed in monthly intervals and pill counts for each
drug were performed at the next visit to assess treatment
adherence. Follow-up visits were performed at 2, 4, 8, 12,
and 24 weeks after treatment initiation. Primary outcome
assessments at baseline and subsequent visits included
plasma HIV RNA (COBAS TaqManV2; Roche Mol-
ecular Systems, Branchburg, New Jersey, USA) and CD4þ
cell counts (FACSCount system; BD Bioscience, San Jose,
California, USA), the latter not performed at week 2.
Virological failure was defined as two consecutive HIV
RNA measurements more than 1000 copies/ml at week 12
or later. Genotypic resistance testing was performed at the
time of virological failure and from stored baseline samples
in these cases to assess preexisting resistance before
treatment. At baseline and each subsequent visit, safety
assessments were performed, including physical assess-
ments, Hb, complete blood count and platelets, biochem-
istry (creatinine, ALT, aspartate aminotransferase, gamma-
glutamyltransferase, bilirubin, amylase, and glucose) and
urine pregnancy testing in women. Metabolic (total
cholesterol, triglycerides, and lactate) were collected at
baseline, week 12, and 24. All laboratory tests were
performed at the Centre de Diagnostic et de Recherches
sur le SIDA (CeDReS) in Abidjan and at the NIMR-
Mbeya Medical Research Center main laboratory in
Mbeya. Both laboratories implement strict internal quality
control programmes and participate in external proficiency
testing programmes, including accreditation by the
College of American Pathologists (CAP) in Mbeya and
by AfriQualab (AFQL) in Abidjan.
Treatment-emergent clinical adverse events were defined
as any new or worsening previous clinical condition after
ART initiation and reported according to severity and
relationship to study treatments. Laboratory events were
considered as clinical adverse events if they required
intervention (e.g. treatment for anaemia, neutropenia-
associated interruption of cotrimoxazole prophylaxis),
serious adverse events reporting included grade 4
laboratory events. Clinical and laboratory adverse events
were graded using the Agence Nationale de Recherches
sur le Sida (ANRS) Toxicity Scale (Version 1.0 translated
to English from the French Version 6.0) [11]. Because we
found large discrepancies between ANRS toxicity and
site-specific reference ranges for lactate, values were
graded retrospectively using local reference ranges. At
week 24, all patients receiving FZD were switched to
either ZDV or tenofovir at the discretion of the
investigator and the local HIV clinic. Copyright © 2017 Wolters KluwePharmacokinetics assessments at baseline and week 4 for
steady-state analysis were planned for 24 participants (six
per study arm) on a first come, first-serve basis.
Pharmacokinetics assignments were balanced by study
site (three patients per arm and site) and sex with a least
30% representation of each sex per arm. Pharmacoki-
netics sampling included repeated blood and urine
collections over a 12-h period for b.i.d. regimens (arms
A and D) and a 24-h period for o.d. regimens (arms B and
C; pharmacokinetics details in the supplement, http://
links.lww.com/QAD/B27).
Outcomes
The primary outcome was the proportion of patients with
plasma HIV RNA less than 50 copies/ml at week 24.
Secondary efficacy outcomes included the proportion of
patients with plasma HIV RNA less than 400 copies/ml,
and change in log10 viral load and in CD4
þ cell counts
through week 24. The primary safety analyses included
grade III/IV clinical and laboratory adverse events,
focused analysis involved events related to myelotoxicity.
Pharmacokinetics outcomes included plasma and urine
concentrations of FZD, ZDV, and ZDV–glucuronide
after the first treatment dose and at steady state (week 4).
Statistical analysis
The study was designed as proof of concept to demonstrate
treatment efficacyof FZD-basedART. Intent-to-treat (ITT)
analyses included all patients who received at least one dose
of study drug, with missing outcome data classified as failure.
Per-protocol analyses included all patients who stayed on
treatment until week 24 without substantial treatment
interruption and moderate or good adherence for at least
65% of visits. Safety analyses included all participants who
received at least one doseof study regimen and all time points
up to 14 days after the last dose of study regimen (for patients
who discontinued treatment) or until week 24. To facilitate
comparison of FZD and ZDV, safety and other analyses were
not only performed separately for each arm, but also on
pooled data for all FZD arms. Treatment adherence was
calculated as the numberof pills taken dividedby the number
of pills supposed to be taken, expressed as a percentage.
Descriptive analyses report the median and interquartile
range (IQR) for continuous variables and the number and
percentage of participants in each stratum for binary and
categorical variables, confidence intervals for percentages
were calculated using the exact or Clopper–Pearson
binomial formula. To compare binary outcomes between
arms, we report risk ratios and their accompanying
confidence interval or Fisher’s exact P value. All reported
P values are two sided and for all statistical tests an a level
of less than 0.05 denotes significance. Stata statistics
software (version 14; StataCorp, College Station, Texas,
USA) was used to perform statistical analyses and to draw
graphs. Pharmacokinetics noncompartmental analysis
was performed using Phoenix WinNonlin 6.4 software
(Certara USA, Inc., Princeton, New Jersey, USA).r Health, Inc. All rights reserved.
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3 disconnued treatments
1 lost to follow up§
1 withdrew consent§
1 pregnancy
30 assigned to Am A
FZD 600mg b.i.d.
30 included in ITT and safety 
analysis
27 included in PP analysis 
7 disconnued treatments
1 moved to village
1 withdrew consent§
1 pregnancy
1 eligibility deviaon
3 adverse events‡
29 assigned to Arm B
FZD 800mg o.d.
29 included in ITT and safety 
analysis
22 included in PP analysis
2 disconnued treatments‡
1 adverse event‡
1 death
2 excluded from PP analysis 
due to poor treatment 
adherence or not available 
HIV-RNA at W24
29 assigned to Arm C
FZD 1200mg o.d.
29 included in ITT and safety 
analysis
25 included in PP analysis
2 disconnued treatments
1 adverse event‡
1 virological failure*
1 excluded from PP analysis 
due to substanal 
interrupon of study 
medicaons
31 assigned to Arm D
ZDV 300mg b.i.d.
31 included in ITT and safety 
analysis
28 included in PP analysis
220 paents assessed for eligibility
1 withdrew consent before ART iniaon §
119 started on study treatment
120 randomized
Fig. 1. Study profile. FZD, fozivudine; ZDV, zidovudine; b.i.d., twice daily; o.d., once daily; PP, per-protocol; ITT, intent-to-treat.
Retrospectively detected transmitted drug resistance prior to randomization. zAdverse event included: FZD Arm B: IV anaemia
(1), IV GGT elevation (1), Kaposi’s sarcoma and chemotherapy (1); FZD Arm C: death due to cholangiocellular carcinoma (1),
severe rash probably related to efavirenz (1), ZDV arm: IV anaemia (1). §Lost to follow-up and withdrawn consent between study
week 2 and 8 were mainly due because of being not ready to take antiretroviral therapy.Results
Between 7 January 2013 and 8 January 2014, we recruited
120 patients who were randomly assigned to the four
study arms (Fig. 1). One patient who withdrew consent
prior to first intake of study regimen was excluded from
analysis. Of the remaining 119 patients, 14 (11.8%)
patients did not complete the study treatments with
reasons indicated in Fig. 1. Baseline demographic and
HIV disease characteristics were balanced between study
arms (Table 1). Overall 38 patients were in WHO stage 3
or 4 and more often assigned to arms A and C (40 and
38%, respectively). Diseases included tuberculosis (TB)
(N¼ 10, of those six patients were still on stable TB
treatment at inclusion), sever weight loss (N¼ 8),
unexplained diarrhoea (N¼ 6), unexplained fever
(N¼ 9), persistent oral thrush (N¼ 4), sever bacterial
infection (N¼ 7), or chronic herpes simplex virus
infection (N¼ 1). In all patients, disease was either
controlled or not considered to be severe at the time
of inclusion.
Treatment outcomes
At week 24, the proportion of patients with HIV
RNA loads less than 50 and with less than 400 copies/ml
was similar in the four treatment arms, both, according to
the ITTand the per-protocol analysis (Table 2). The ITT
analysis resulted in 73% virological responses less than
50 copies/ml in the combined FZD arms versus 77% in Copyright © 2017 Wolters Kluwer Hthe ZDV arm. Response rates were balanced between
FZD arms, with the lowest proportions of responders
seen in arm B. Here, the difference in the response for a
threshold less than 400 copies/ml was lower than in the
ZDVarm (69 versus 90%). According to the per-protocol
analysis, virological responses less than 50 copies/ml were
87% for the combined FZD arms versus 79% in the ZDV
arm, with outcomes balanced between FZD arms.
The median HIV log10 decrease from baseline to week 24
was 3.7 (IQR 4.3 to 3.2) in the combined FZD
arms versus 4.0 (IQR 4.3 to 3.4) in the ZDV arm
(Fig. 2), the median absolute CD4þ cell count increase
was 99 cells/ml (IQR 52–181) versus 79 cells/ml (IQR
65–144), respectively, with similar values seen across all
treatment arms (suppl. Figure 1, http://links.lww.com/
QAD/B26). Confirmed virological treatment failure was
observed in four (3.4%) patients until week 24, with one
case each in arms B and C, and two cases in arm D.
Genotypic resistance testing revealed the selection of the
K103N non-nucleoside reverse transcriptase inhibitors
mutations but no NRTI mutations in all of these patients
at the time of virological failure (two patients with
subtype CRF02_AG from Côte d’Ivoire and two with
subtype C from Tanzania). In one patient receiving ZDV
confirmed virological failure occurred already at week 12
and retrospective analysis from baseline samples revealed
preexistence of the K103N mutation prior to treatment
initiation.ealth, Inc. All rights reserved.
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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Table 2. Proportion of patients with HIV RNA less than 50 and less than 400 copies/ml in intent-to-treat and per protocol analysis.
Arm A FZD
600 mg b.i.d.
Arm B FZD
800 mg o.d.
Arm C FZD
1200 mg o.d.
FZD arms
combined
Arm D ZDV
300 mg b.i.d.
All arms
combined
Intent-to-treat analysis
HIV RNA<50 copies/mla 24/30
(80%; 61–92%)
19/29
(66%; 46–82%)
21/29
(72%; 53–87%)
64/88
(73%; 62–82%)
24/31
(77%; 59–90%)
88/119
(74%; 65–82%)
Risk ratio
(95% CI)b
1.03
(0.80–1.34)
0.85
(0.61–1.17)
0.94
(0.70–1.26)
0.94
(0.75–1.18)
NA NA
Risk difference
(%; 95% CI)b
2.6
(18.0 to 23.1)
11.9
(34.6 to 10.8)
5.0
(26.9 to 16.9)
4.7
(22.1 to 12.7)
NA NA
HIV RNA<400 copies/mla 25/30
(83%; 65–94%)
20/29
(69%; 49–85%)
23/29
(79%; 60–92%)
68/88
(77%; 67–86%)
28/31
(90%; 74–98%)
96/119
(81%; 72–87%)
Risk ratio
(95% CI)b
0.92
(0.76–1.12)
0.76
(0.58–1.00)
0.88
(0.71–1.09)
0.86
(0.73–1.01)
NA NA
Risk difference
(%; 95% CI)b
7.0
(23.9 to 9.9)
21.4
(41.2 to 1.6)
11.0
(29.1 to 7.0)
13.1
(26.7 to 0.6)
NA NA
Per protocol analysis
HIV RNA<50 copies/mla 24/27
(89%; 71–98%)
19/22
(86%; 65–97%)
21/25
(84%; 64–96%)
64/74
(87%; 77–93%)
23/29
(79%; 60–92%)
87/103
(85%; 76–91%)
Risk ratio
(95% CI)b
1.12
(0.89–1.41)
1.09
(0.85–1.40)
1.06
(0.82–1.36)
1.09
(0.89–1.34)
NA NA
Risk difference
(%; 95% CI)b
6.6
(9.3 to 28.5)
7.1
(13.5 to 27.6)
4.7
(15.9 to 25.3)
7.2
(9.5 to 23.9)
NA NA
HIV RNA<400 copies/mla 25/27
(93%; 76–99%)
20/22
(91%; 71–99%)
23/25
(92%; 74–99%)
68/74
(92%; 83–97%)
27/29
(93%; 77–99%)
95/103
(92%; 85–97%)
Risk ratio
(95% CI)b
0.99
(0.86–1.15)
0.98
(0.83–1.15)
0.99
(0.85–1.15)
0.99
(0.88–1.11)
NA NA
Risk difference
(%; 95% CI)b
0.5
(14.0 to 13.0)
2.2
(17.3 to 13.0)
1.1
(15.2 to 13.0)
1.2
(12.3 to 9.9)
NA NA
b.i.d., twice daily; CI, confidence interval; FZD, fozivudine; NA, not applicable; o.d., once daily; ZDV, zidovudine.
aData shown are n/N (%; 95% exact/Clopper–Pearson confidence interval).
bCompared with arm D.
Table 1. Baseline characteristics and HIV status of the safety population.
Arm A FZD 600 mg
b.i.d. (n¼30)
Arm B FZD
800 mg o.d. (n¼29)
Arm C FZD 1200 mg
o.d. (n¼29)
Arm D ZDV 300 mg
b.i.d. (n¼31)
All
(n¼119)
Study site
Abidjan 15 (50%) 14 (48%) 14 (48%) 16 (52%) 59 (50%)
Mbeya 15 (50%) 15 (52%) 15 (52%) 15 (48%) 60 (50%)
Sex
Women 19 (63%) 19 (66%) 19 (66%) 21 (68%) 78 (66%)
Men 11 (37%) 10 (34%) 10 (34%) 10 (32%) 41 (34%)
Age (years) 37 (32–41) 36 (34–45) 38 (34–46) 39 (32–46) 38 (32–45)
BMI (kg/m2) 22.8 (20.9–25.4) 22.1 (21.0–24.5) 230 (20.1–26.0) 23.9 (21.5–27.2) 23.0 (20.7–25.8)
WHO Stage
Stage 1 or 2 18 (60%) 22 (76%) 18 (62%) 23 (74%) 81 (68%)
Stage 3 or 4 12 (40%) 7 (24%) 11 (38%) 8 (26%) 38 (32%)
Started or on
cotrimoxazole prophylaxis
28 (93%) 27 (93%) 26 (90%) 29 (97%) 110 (93%)
HIV RNA log10 (copies/ml) 5.2 (4.7–5.5) 5.2 (4.4–5.5) 4.9 (4.5–5.3) 5.1 (4.5–5.6) 5.1 (4.5–5.4)
HIV RNAa
<100 copies/ml 13 (43%) 12 (41%) 17 (59%) 12 (39%) 54 (45%)
100 copies/ml 16 (53%) 17 (59%) 12 (41%) 19 (61%) 64 (54%)
CD4þ cell count (cells/ml) 241 (172–295) 223 (161–291) 257 (220–303) 205 (142–264) 235 (167–297)
CD4þ cell count categories
200 cells/ml 19 (63%) 17 (59%) 22 (76%) 17 (55%) 75 (63%)
<200 cells/ml 11 (37%) 12 (41%) 7 (24%) 14 (45%) 44 (37%)
Haemoglobin (g/dl) 12.1 (11.2–13.3) 11.9 (10.7–13.0) 11.3 (10.9–13.1) 11.7 (11.0–14.0) 11.9 (11.0–13.3)
Neutrophils (cells/ml103) 1.50 (1.35–2.01) 1.49 (1.02–2.02) 1.73 (1.38–2.94) 1.79 (1.35–2.33) 1.66 (1.28–2.31)
Grade I 12 (40%) 8 (28%) 7 (24%) 11 (35%) 38 (32%)
Grade II 3 (10%) 6 (21%) 1 (3%) 2 (6%) 12 (10%)
Grade III 0 1 (3%) 2 (7%) 0 3 (3%)
Data are median (IQR) or n (%). b.i.d., twice daily; FZD, fozivudine; o.d., once daily; ZDV, zidovudine.
aN¼1 HIV RNA at baseline missing for arm A.
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Fig. 2. Change in median HIV-1 RNA log10 viral load in the
intent-to-treat population since baseline (only study treat-
ment emergent values reported, error bars indicate inter-
quartile range). b.i.d., twice daily; FZD, fozivudine; o.d.,
once daily; ZDV, zidovudine.Safety assessments
Mean time of exposure to study regimen was similar in
the combined FZD and the ZDVarms (Table 3). Overall,
299 treatment-emergent clinical adverse events were
reported, which occurred in 86% of patient receiving Copyright © 2017 Wolters Kluwer H
Table 3. Treatment emergent adverse events.
FZD
Weeks of treatment exposure, mean (SD)
Any adverse event
Adverse events related to study treatment
Grade 3 or 4 adverse events
Serious adverse events
Serious adverse events related to study treatment
Adverse events leading to study treatment discontinuation
Most common treatment emerging adverse events (>5% overall)
Nausea, vomiting
Dizziness, vertigo
Nasopharyngitis, tonsillitis
Upper respiratory tract infection
Asthenia, fatigue, somnolence
Headache
Gastritis, dyspepsia, abdominal pain
Gastroenteritis, diarrhoea
Influenza-like illness
Cough
Rash
Genital infection, pelvic inflammatory disease
Grade 3–4 laboratory abnormalities (new or worsening)
Anaemia, haemoglobin, <7 g/dl
Leukopenia, <2000 cells/ml
Neutropenia, <750 cells/ml
Thrombocytopenia, <50 000 cells/ml
Aspartate aminotransferase, >5ULN
g-Glutamyl transferase, >5ULN
FZD, fozivudine; SAE, serious adverse event; ULN, upper limit of normal;
aCalculated using Fisher’s exact formula.
bOne patients reported with three SAEs (septicaemia secondary to urinary
cFZD arms: IV anaemia (1), IV GGT elevation (1), TB-IRIS (1), KS-IRIS (1),
dFZD arms: IV anaemia (1), IV GGT elevation (1), death because of cholang
Kaposi’s sarcoma and chemotherapy (1); ZDV arm: IV anaemia (1).FZD and in 84% receiving ZDV, with most events being
mild or moderate. Type and frequencies of common
clinical adverse events were balanced between all four
arms. Six patients were taken off study treatments because
of adverse events with reasons indicated in Table 3. Of
note, two patients experienced possibly treatment-related
grade IVanaemias, which required blood transfusion and
were reported as serious adverse events. One of these
anaemic patients received ZDV and the other FZD (arm
B), the latter was diagnosed with a sickle cell trait,
implying other possible triggers for anaemia. In total, 19
serious adverse events (SAEs) were reported in 17 patients
and 12 SAEs were considered as treatment related. Of
those, seven were based on clinically asymptomatic,
transient grade IV neutropenia (five related to ZDV and
two to FZD), which prompted temporary interruption of
cotrimoxazole prophylaxis. The remaining five included
the two cases of anaemia mentioned above, two cases
were related to immune reconstitution syndromes
associated with TB (arm A) and Kaposi’s sarcoma (arm
B), which required hospitalization, and one case (arm B)
was based on transient grade IV g-glutamyl transferase,
and mild-to-moderate liver transaminases elevation
mainly because of extensive alcohol abuse. This case
was reported as treatment related based on possibly added
antiretroviral drug toxicity.ealth, Inc. All rights reserved.
arms (N¼88) ZDV arm (N¼31) P valuea
21.7 (5.99) 23.5 (2.48) 0.117
76 (86%) 26 (84%) 0.768
45 (51%) 15 (48%) 0.837
12 (14%) 6 (19%) 0.560
10 (11%) 7 (23%)b 0.142
6 (7%)c 6 (19%)c 0.077
5 (6%)d 1 (3%)d 0.606
16 (18%) 5 (16%) 1
15 (17%) 3 (10%) 0.396
11 (13%) 4 (13%) 1
7 (8%) 7 (23%) 0.048
12 (14%) 1 (3%) 0.180
10 (11%) 3 (10%) 1
8 (9%) 4 (13%) 0.508
8 (9%) 2 (7%) 1
7 (8%) 3 (10%) 0.719
4 (5%) 3 (10%) 0.375
6 (7%) 1 (3%) 0.675
7 (8%) 2 (7%) 1
1 (1%) 1 (3%) 0.455
3 (3%) 4 (13%) 0.074
19 (22%) 13 (42%) 0.035
1 (1%) 0 1
1 (1%) 1 (3%) 0.455
6 (7%) 1 (3%) 0.606
ZDV, zidovudine.
tract infections, cataract surgery, and IV neutropenia).
IV neutropenia (2); ZDV arm: IV anaemia (1), IV neutropenia (5).
iocellular carcinoma (1), severe rash probably related to efavirenz (1),
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especially focused. Comparing the combined FZD arms
with the ZDVarm, anaemia of any gradewas observed in 11
versus 23% (P¼ 0.142), grade III/IVanaemia in1 versus 3%
(P¼ 0.455), and grade III/IV neutropenia in 22 versus 42%
(P¼ 0.035), respectively. A decrease of Hb levels and
absolute neutrophil counts was observed in all arms, with
lowest values seen at 4 weeks after treatment initiation with
a median Hb decrease from baseline of 0.4 versus 0.9 g/dl
(P¼ 0.033) in patients receiving FZD and ZDV, and a
median neutrophil decrease of 269 versus 864 cells/ml
(P¼ 0.004), respectively (Supplemental Figures 2 and 3,
http://links.lww.com/QAD/B26). Transient mild or
moderate creatinine elevation was seen in 3 versus 10%,
and liver transaminase elevation in 10 versus 13% of patients
receiving FZD and ZDV, respectively. Severe or worse liver
transaminases were additionally observed in two patients
which was associated with diseases (alcohol induced
hepatitis, septicaemia). Elevated g-glutamyl transferases
were frequent (35% of patients). Mild or moderate transient
hyperglycaemia was overall observed in 13%, hypoglycae-
mia in 12%, hypercholesterinaemia in 11%, and hyper-
triglyceridemia in 1% of patients; events were balanced
between arms (Supplemental Table 1, http://links.lww.-
com/QAD/B26). Clinically asymptomatic hyperlactaemia
was observed in two patients receiving FZD.
Pharmacokinetic assessments
Pharmacokinetics results for FZD, ZDV, and ZDV–
glucuronide were available for 24 patients (Supplemental
Table 1, http://links.lww.com/QAD/B26).AdelayofFZD
absorption after the first dosewas observed with a mean time
to quantifiable plasma concentration of about 2 h in the
600 mg b.i.d. and 800 mg o.d. arms, and 1 h in the 1200 mg
o.d. arm. The time to maximum FZD concentration (Tmax)
did not vary depending on the dose or the kinetic (first dose
or steady state) with a mean of 6.8 (SD 0.6) versus 2.2 h for
the ZDV. The FZD elimination half-life was around 5.4 h
for arms A and B regardless of the kinetic and slightly higher
for arm C (7.2 and 7.5 h for week 0 and 4, respectively).
Although we found dose linearity from 600 to 1200 mg by
maximum FZD concentration after initial drug adminis-
tration, linearity was not demonstrated at steady state for
both o.d. FZD regimens, which was likely because of
interpatient variability. Two patients from the 800 mg arm
presented with very high maximum concentrations and
without these two high values the previous observed
linearity would have been conserved. Comparison between
average concentrations, calculated after the first dose and at
steady state, showed a weak accumulation factor of about
1.35 for FZD in the two o.d. arms. As expected, a greater
accumulation factor around 2.1 was found for the b.i.d.
regimen because of the higher dosing frequency. Similarly,
trough concentrations at steady state were lower in the o.d.
(mean 1.31 and 1.69 mg/ml for arms B and C, respectively)
than those in the b.i.d. arm (mean 3.42 mg/ml), but still
much higher than the 50% inhibitory concentration of FZD
for HIV-1 (15–150 ng/ml). Copyright © 2017 Wolters KluweA delayed Tmax and prolonged elimination half-life was also
observed forZDVand for theZDV–glucuronidemetabolite
within the FZD arms, with values very close to those seen in
the FZD pharmacokinetic, indicating a slow FZD
absorption and constant transformation of FZD into
ZDV. The metabolization of ZDV to ZDV–glucuronide
did not present a limiting step at any dose since the observed
Tmax and elimination half-lives of ZDV–glucuronide were
very close to those in the ZDVarm. FZD was not detectable
in urine. At steady state, around 4.5% of the parent
compound and 64% of the glucuronide form was recovered
in the urine in the ZDVarm. On a molar basis, mean urinary
ZDV and ZDV–glucuronide excretion was found around
2.2 and 21%, respectively, of the dose in the FZD arms.
Discussion
Our study demonstrates treatment efficacy and overall
good tolerability of FZD-based antiretroviral treatment
regimens over a period of 24 weeks in an HIV-infected,
ART-naive, African population. Response rates in FZD
and ZDVarms were similar, especially when analysed per-
protocol, which best reflects treatment potency. For our
primary prespecified ITTendpoint, the response rate was
lowest in the FZD 800 mg o.d. arm because of higher
numbers of noncompletion compared with the other study
arms. Because sample size was low, we think that this
observation should be interpreted with caution. We also
want to point out that one patient receiving ZDV with
early virological treatment failure had a preexisting non-
nucleoside reverse transcriptase inhibitors mutation, which
was not an exclusion criterion in our ITT analysis. If this
patient would have been excluded from analysis, the
response rate for the ZDV arm would have been slightly
better (80% with a virological response below 50 copies/
ml); however, this would not significantly impact the
primary endpoint. Our response rates are comparable with
those reported from previously published studies reporting
24-week data in treatment-naive patients receiving ZDV,
3TC, and EFV, such as the Prospective Evaluation of
Antiretrovirals inResourceLimitedSetting study (PEARLS)
[12] and outcomes from the 934 Study Group [13,14].
Our data furthermore demonstrate the potential of o.d.
FZD administration as virological response rates of the o.d.
and the b.i.d. arms were similar, which was further
supported by pharmacokinetic outcomes. As shown in
previous studies [8–10], a long FZD elimination half-life
and a delayed FZD absorption was observed. This is
consistent with a delayed release of the drug from
the formulation or slow absorption in the upper part of
the gut possiblybecauseofweakpermeabilityor membrane
transporters efflux activity. These characteristics point out
an umbrella-like pharmacokinetic profile which provides
constant drug levels allowing for once daily dosing.
In line with previous reports, concentrations of ZDVand
ZDV–glucuronide in the FZD arms were much lowerr Health, Inc. All rights reserved.
508 AIDS 2017, Vol 31 No 4than those measured in the ZDV arms. This, apart from
the FZD selectivity for mononuclear cells and very low
activity in red blood and stem cells, probably explain a
reduced risk for haematologic toxicity in patients
receiving FZD. Our study found a lower prevalence of
severe or worse neutropenia and a lower decrease of Hb
levels and absolute neutrophil counts within the first
weeks after FZD exposure compared with patients
receiving ZDV. Although these observations might be of
marginal clinical relevance and need to be cautiously
interpreted because of low sample size and inter-patient
variability, they might indicate lower haemotoxicity for
FZD-based regimens.
Intracellularly, NRTIs undergo three sequential phos-
phorylations leading to the therapeutically active tripho-
sphate metabolites [15]. Preclinical data showed that FZD
is directly cleaved intracellularly to ZDV-monophos-
phate, indicating that the first phosphorylation step is not
necessary for FZD. Given a slow transformation rate from
FZD to ZDV and assuming that, after FZD exposure,
conversion to ZDV-monophosphate is not the limiting
step, intracellular accumulation of ZDV-monophosphate
seems likely. ZDV-monophosphate has been associated
with increased cell or mitochondrial toxicity [16–18]
linked to metabolic toxicity and lipodystrophy syndrome.
In our study, metabolic abnormalities were transient and
infrequent, with similar proportions seen in the study
arms. Given the relatively short drug exposure time, we
did not investigate for clinical features of lipoatrophy.
Samples for the analysis of intracellular phosphorylated
ZDV metabolite levels after FZD exposure were collected
in our study, and will be published later.
Generalizability of our results is limited by small sample
size, and favouring a o.d. regimen we cannot clearly
conclude if 800 or 1200 mg o.d. FZD would be better.
However, our study provides promising evidence to
further advance into larger efficacy trials investigating
FZD as a o.d. thymidine analogue NRTI. FZD has the
potential to replace ZDV as a potentially toxicity
improved part of NRTI backbones in antiretroviral
therapy, maintaining the distinct characteristics of
thymidine analogue NRTI drug resistance patterns
relevant in antiretroviral treatment strategies, thus
providing an alternative to tenofovir or abacavir-based
regimens in first and second-line antiretroviral treatments.Acknowledgements
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